title: Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats.
abstract: The effects of blockade of the renin-angiotensin system at three different sites on regression of left ventricular hypertrophy (LVH) were investigated in spontaneously hypertensive rats (SHRs). Angiotensin-converting-enzyme (ACE) inhibitor, angiotensin II type 1 (AT1) receptor antagonist, renin inhibitor, or the combination of hydralazine and hydrochlorothiazide was administered for 7 days to SHRs to obtain the same decrease in blood pressure. Treatment with ACE inhibitor, AT1 receptor antagonist, or renin inhibitor significantly decreased left ventricular mass. On the other hand, hydralazine administration failed to diminish LVH in SHRs. These findings indicate that blockade of the renin-angiotensin system regressed LVH irrespective of the site of the blockade and independent of hemodynamic changes.
authors.affiliation: Ehime University School of Medicine, Shigenobu-cho, Onsen-gun, Ehime, Japan.
authors.forename: Q
authors.initials: Q
authors.lastname: Zhang
authors.forename: K
authors.initials: K
authors.lastname: Kohara
authors.forename: H Y
authors.initials: HY
authors.lastname: Qui
authors.forename: K
authors.initials: K
authors.lastname: Hiwada
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004359:Drug Therapy, Combination; D006339:Heart Rate / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000473:pathology; D006830:Hydralazine / Q000627:therapeutic use; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications* / Q000473:pathology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007189:Indans / Q000627:therapeutic use; D008297:Male; D009929:Organ Size; D051381:Rats; D011918:Rats, Inbred SHR; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles; D000092502:Renin Inhibitors
chemical_list: D000804:Angiotensin II; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D006830:Hydralazine; D006852:Hydrochlorothiazide; D007189:Indans; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D013777:Tetrazoles; D000092502:Renin Inhibitors; C077793:candesartan cilexetil; C047759:delapril